What Oftan Starine treats: main uses and benefits

Oftan Starine is used to provide temporary symptomatic relief for minor eye irritation and associated visible redness.

This medication is intended for short-term symptom management of physical discomfort, including visible eye redness, burning, and stinging associated with episodic exposure to external factors. It is applied in addressing symptom clusters triggered by acute environmental changes, such as exposure to dust, smoke, wind, or swimming. Oftan Starine supports the management of discomfort during these specific episodes.

Supportive Management of Ocular Discomfort

Oftan Starine assists with addressing visible eye redness and injection. It is relevant for supportive symptom management when symptoms appear suddenly in the eye. This approach helps to ease the overall symptom burden and contributes to improved comfort during periods of heightened irritation.

Regulatory References

1. NIH MedlinePlus overview of Tetrahydrozoline Ophthalmic

Eligibility Map: Who can and cannot use Oftan Starine — official regulatory information

Note: Oftan Starine is not an FDA-approved or EMA-authorized medicinal product. The following eligibility profile is based on restrictions for related substances that may be confused with this name, such as the investigational drug Ostarine (a Selective Androgen Receptor Modulator, or SARM).

Eligibility scope

Populations for whom use is allowed (as stated in label): None (Not an approved medicine). Populations for whom use is not recommended (if applicable): Individuals with a history of liver problems. Populations for whom use is contraindicated: Pregnant or breastfeeding individuals. Age-related eligibility rules: Pediatric use not established. Adults are the target of current investigational trials. Condition-specific eligibility rules: Use is restricted in the presence of liver problems due to the potential for liver damage. Pregnancy and lactation eligibility status (if explicitly documented): Avoid use (Not enough reliable information available to confirm safety; use is not recommended). Eligibility-related restrictions: Banned by the World Anti-Doping Agency (WADA) and the NCAA.

Eligibility classifications (high-level)

Eligibility severity classification (as defined in official documents): Possibly Unsafe (due to risk of liver damage and other serious effects). Regulatory basis (EMA / FDA / etc.): Not approved for any use (Investigational drug status). Eligibility-context constraints (as defined in official documents): Use is prohibited in organized sports/doping contexts.

Resulting eligibility structure

Official eligibility statements:

• The substance is not approved for any medical use by the U.S. FDA or European EMA.
• Its use is generally considered possibly unsafe due to risks including liver damage and heart problems.
• Individuals with liver problems, those who are pregnant, or those who are breastfeeding should strictly avoid use.

Connection to the overall eligibility profile (2–4 sentences): The official regulatory profile strictly defines that this substance is not an approved medicine, classifying its use as unestablished and potentially unsafe. Eligibility is officially constrained by the lack of regulatory approval and documented risks of serious adverse effects, which prohibits its use in certain physiological states and in individuals with pre-existing conditions like liver impairment. Any use outside of a regulated clinical trial is not sanctioned by major health authorities.

The regulatory profile for Oftan Starine (Tetryzoline Hydrochloride) focuses on critical constraints derived from the potential for minimal systemic absorption of this sympathomimetic amine. Official documentation establishes specific restrictions regarding co-administration with other medicines that influence the body's adrenergic system.

Restricted Medicinal Combinations

The most significant restriction is the formal prohibition against concurrent use with Monoamine Oxidase Inhibitors (MAOIs). This combination is classified as contraindicated because it creates a risk of severe pharmacodynamic potentiation, which may lead to an acute hypertensive crisis. This critical restriction also applies to use within a 14-day period following the discontinuation of an MAOI. Cautionary statements are further documented for use with other drug classes. This includes Tricyclic Antidepressants and other systemically or topically applied Sympathomimetic Amines, due to the potential for additive effects resulting in an elevated heart rate or high blood pressure. Caution is also advised regarding use prior to general anesthesia involving agents that sensitize the heart muscle to sympathomimetics, such as halothane.

Interactions with Underlying Conditions

The medicine is formally contraindicated for patients diagnosed with narrow-angle glaucoma. This is a critical restriction where the drug’s action can precipitate an acute ocular event by interacting with the existing condition. Additionally, regulatory guidance includes specific warnings for patients with pre-existing conditions such as hypertension, diabetes mellitus, hyperthyroidism, or coronary artery disease, where the risk of adverse systemic effects from drug absorption is increased. No specific interactions with food, alcohol, or herbal products are documented in the official regulatory labeling for this product.

The mechanism of action for Oftan Starine (Tetryzoline) involves the modulation of local vascular tone, achieved by engaging local sympathetic nervous system pathways. Oftan Starine is a selective agonist of the Alpha-1 (alpha1) Adrenergic Receptor, which are excitatory receptors located on the smooth muscle of the conjunctival arterioles. By activating these receptors, the molecule mimics the effects of endogenous norepinephrine, thereby initiating a molecular cascade that changes vessel caliber. Activation of the alpha1-AR triggers the G q protein signaling pathway, leading to a rapid surge in intracellular calcium ( Ca^2+) within the smooth muscle cells. This calcium increase forces the muscle cells to contract, resulting in immediate vasoconstriction—the narrowing of the local blood vessels. This physiological narrowing diminishes the volume of blood contained within the local vessels, which is the mechanism's primary output. Sustained stimulation of the alpha1-ARs induces adaptive responses, including receptor desensitization (Tachyphylaxis), causing a functional loss of alpha1-AR responsiveness over time. Furthermore, the localized reduction in blood flow can trigger counter-regulatory mechanisms that increase the urge for vasodilation, leading to an exaggerated, compensatory vasodilation upon cessation of the drug.

How to Use Oftan Starine

Oftan Starine is an ophthalmic solution containing 0.05% Tetryzoline Hydrochloride, which is administered through the topical ophthalmic route only. Usage is characterized by specific parameters regarding dose quantity, frequency, and duration of application.

Administration Protocol

The standard high-level dosing regimen consists of instilling one to two drops into the affected eye(s) as needed. This dose may be repeated up to four times per day (approximately every six hours). The medication is not intended for a continuous or long-term scheduled regimen.

Procedural Guidelines

Procedural instructions involve the removal of contact lenses prior to application and emphasize the importance of maintaining the sterility of the solution. To prevent contamination, the tip of the container must not make contact with the eye or any other surface. The drug is exclusively for as-needed use, and the strict 72-hour limit defines its role as a short-course topical application.

Research Evidence / Overview of Studies for Oftan Starine

The research base for Oftan Starine (tetryzoline) focuses on its approved use for temporary symptom relief. Because this is a medication established for minor, short-term issues, the research often involves acute, short-duration studies to understand temporary effects on symptoms.

Evidence for the Temporary Relief of Minor Eye Redness

Research has was studied for how Oftan Starine affects visible eye redness, a condition often resulting from minor irritation. The evidence base includes foundational data that led to the ingredient's classification as Generally Recognized as Safe and Effective (GRASE). Evidence includes short-term Randomized Controlled Trials (RCTs). These trials research examined outcomes related to physical discomfort by measuring changes in clinician-assessed ocular redness using standardized scales.

Studies explored how quickly changes in redness was observed in adult populations experiencing minor or moderate eye redness. The findings describe patterns observed in the studies related to temporary changes. Studies reported observations of changes measured shortly after use. This evidence contributes to understanding symptom patterns related to acute redness.

Studies Examining Relief of Associated Minor Irritation

This part outlines the research that specifically focused on patient experience beyond just visible redness. Studies monitored the impact on outcomes related to physical discomfort, such as patient-reported outcomes describing perceived discomfort, burning, and stinging. These trials applied in studies examining patient-reported experiences to understand the outcomes related to symptomatic changes observed during the study period.

The research exploring short-term symptom changes reported that patient-reported outcomes describing perceived discomfort were assessed shortly after administration. Findings help contextualize how patients reported their experience during episodes where symptoms become more noticeable. This body of research was evaluated in settings with varying symptom burdens to examine changes in short-term symptom activity in different acute scenarios.

Duration of Effect and Follow-up in Clinical Research

The research structure for Oftan Starine centers on understanding immediate changes. Studies used in research exploring how symptoms change over time primarily focused on the onset of action. Acute studies of symptom changes monitored outcomes at very short time intervals following administration. This research explores short-term symptom changes to define how quickly the change begins.

Observation periods in acute efficacy trials were limited and typically covered a duration of less than 24 hours. This short follow-up duration aligns with the purpose of the medicine, which is only authorized for temporary, short-term use, generally not exceeding 72 hours. The follow-up durations were limited by the fact that the drug is not intended for long-term use, meaning long-term effects are not fully established.

Research Data on Specific Use Groups

The research base primarily focuses on healthy adult subjects experiencing temporary eye irritation. However, the authorized use of the medication also encompasses the pediatric population ge 6 years for temporary symptom management. Research has was studied for the use of this medication in children, as the product is widely available over-the-counter.

While the primary findings describe group patterns in adults, data for certain groups remain insufficient. For instance, there is limited information for long-term outcomes across any age group, and the research does not determine whether an individual will respond similarly regardless of age or minor underlying health variations. Results apply only to the populations studied and do not provide comprehensive data for use during pregnancy or for patients with complex eye diseases.

Long-Term Studies and Evidence Gaps

The available evidence is limited in terms of continuous use. Since the medication is only intended to address temporary, episodic changes, long-term effects are not fully established through research. This is a critical evidence gap: studies have not explored the outcomes related to extended use or chronic symptom management.

Research describes a specific limitation known as rebound redness (hyperemia). Studies and clinical reports indicate that if the medication is used continuously or for longer periods than recommended, it was associated with the potential for the redness to return and potentially worsen when the medication is stopped. This information contributes to understanding research limitations, and research indicates that data for long-term symptom patterns of this type of decongestant remain limited.

Key Studies & References

1. Tetrahydrozoline Ophthalmic: MedlinePlus Drug Information (NIH)
2. CVP STERILE EYE DROPS- tetrahydrozoline hcl solution - DailyMed - NIH (Official Labeling)

Common questions about Oftan Starine (FAQ)

Q: Can I drink alcohol while taking this medicine?

Official product information suggests avoiding alcohol while taking this medicine. Both alcohol and this medication can increase central nervous system side effects such as dizziness, drowsiness, and having difficulty concentrating. Official product information indicates that combining them may potentially worsen these effects.

Q: Does it make you sleepy?

Yes, official product information lists dizziness and somnolence (sleepiness) as common side effects of this medicine. Due to these potential effects, patients should be cautious about driving or operating complex machinery until they understand exactly how the medicine affects their ability to perform these activities safely.

Q: Is it safe long-term?

Regulatory documents address the effects of both short-term and chronic (long-term) treatment with this medication. They describe known side effects and warnings that may occur during prolonged use, including rare but serious reports like angioedema (swelling beneath the skin) and suicidal thoughts. The official prescribing information also notes the potential for withdrawal symptoms if the medication is stopped suddenly.

Q: Can children 2 years old use it?

According to the official prescribing information, this medicine is approved for use in children aged 1 month and older for a specific condition: as an add-on treatment for partial-onset seizures. This medicine's approval is limited to specific uses; it is not approved for treating other conditions, such as nerve pain or chronic pain syndromes, in the 2-year-old age group.

Storage Requirements

Oftan Starine ophthalmic solution must be stored at controlled room temperature, maintaining a temperature range between 15 C and 25 C (59 F and 77 F). The medication must be protected from excess heat and moisture and kept in its original container with the cap tightly closed.

Disposal Instructions

Expired or unused Oftan Starine must be properly discarded according to local waste regulations. Do not flush the eye drops down the toilet or pour them into a drain unless specific instructions are provided by an official authorized program.